• PDF / 169,241 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 18 Downloads / 188 Views

DOWNLOAD

REPORT

---

1 S

Various toxicities following off-label use: 4 case reports In a retrospective observational study involving 24 patients, who were treated with four factor prothrombin complex concentrate between November 2014 and February 2017, 4 patients [ages and sexes not stated] were described, who developed stroke, myocardial infarct, atrial thrombi or non-occlusive IJ tube thrombi following off-label treatment with four factor prothrombin complex concentrate for coagulopathy [dosages and outcomes not stated]. The patients, who had unspecified anticoagulant-induced coagulopathy, started receiving off-label treatment with four factor prothrombin complex concentrate infusion. In 2–45 days post prothrombin complex concentrate infusion, the patients developed thromboembolic events manifested as stroke (1 patient), myocardial infarct (1 patient), atrial thrombi (1 patient) and non-occlusive IJ tube thrombi (1 patient). Zheng Y, et al. The use of 4F-PCC to correct direct oral anticoagulant-induced coagulopathy: An observational analysis. Transfusion Medicine 30: 304-307, No. 4, Aug 2020. 803514865 Available from: URL: http://doi.org/10.1111/tme.12683

0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 14 Nov 2020 No. 1830